Kintec

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kintec

Understanding Kintec

Kintec is a pharmaceutical treatment designed to address specific metabolic or physiological imbalances within the body. It belongs to a class of medications that interact with targeted biological pathways to manage or alleviate the progression of certain health conditions.

Primary Mechanism

The active components in Kintec work at a cellular level to modulate the production or activity of specific enzymes or proteins. By stabilizing these biological markers, the medication helps maintain a more consistent physiological state. The exact function of Kintec often depends on the underlying condition being treated, as its systemic effects are tailored to restore or support normal biological functions.

General Characteristics

  • Therapeutic Intent: Kintec is utilized to provide long-term management of chronic conditions rather than providing immediate, temporary relief of acute symptoms.
  • Formulation: The medication is typically developed to ensure steady absorption into the bloodstream, allowing for consistent levels of the active ingredient over a set period.
  • Patient Focus: Its use is centered on improving the quality of life for individuals by managing the biochemical drivers of their condition.

Integration into Care

Kintec is typically used as part of a broader health management plan. Because it targets specific biological mechanisms, its role is focused on the stabilization of the body's internal environment. Understanding how Kintec functions can help individuals better comprehend the management of their specific health journey.

Regulatory References

  1. NIH

What side effects are possible with Kintec?

Possible Side Effects and Safety Information

The safety profile of Kintec (Enalapril maleate) is characterized by adverse reactions classified by frequency and associated with specific physiological systems, as defined in official regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently documented side effects are categorized as Very Common (1/10) and include dry cough, dizziness, nausea, and asthenia (lack of strength). Effects classified as Common (1/100 to < 1/10) include headache, hypotension (low blood pressure), syncope (fainting), rash, dyspnea (shortness of breath), and changes in laboratory values like hyperkalaemia (increased serum potassium) and increases in serum creatinine.

Less frequently, Uncommon effects include renal dysfunction or failure, pancreatitis, and impotence. Rare reactions documented in the SmPC include severe conditions such as hepatic failure, hepatitis, and agranulocytosis.


Serious Safety Considerations

The medicine is associated with a risk of Angioedema, which involves rapid and potentially life-threatening swelling of the face, tongue, and throat. This reaction is explicitly highlighted as a serious safety concern in labeling. Excessive hypotension is another documented risk, particularly following the initial dose in high-risk patients, which may lead to serious outcomes like acute renal failure.


Population-Specific Restrictions

Official regulatory documents mandate that Enalapril is contraindicated during pregnancy due to the risk of Fetal Toxicity (fetal injury and death). Furthermore, patients with a history of Angioedema related to any previous ACE inhibitor treatment are restricted from its use. Safety notes also emphasize an increased risk of renal effects in patients with underlying renal artery stenosis.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Kintec (Enalapril)


Overdose Scope

Domain Official Regulatory Statements
Documented overdose presentations Profound hypotension (most prominent feature), dizziness, tachycardia, bradycardia, palpitations, and stupor.
Physiological systems affected (as stated in label) Cardiovascular system (circulatory shock), renal system (acute renal failure), serum electrolytes (hyperkalemia).
Dose-related or exposure-related factors (if applicable) Massive overdose (ingestion of excessive amounts) is associated with the most severe features, including circulatory shock.
Population-specific overdose notes (if applicable) The active metabolite, Enalaprilat, is dialyzable, which may be relevant for removal in severe overdose cases.
Emergency-response statements (as written in official documents) Seek immediate medical attention. Contact a poison control center or emergency services immediately. Hospital monitoring is required.
When immediate medical help is required (label-derived phrasing only) If the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. When severe hypotension is suspected.

Overdose Classifications (High-Level)

Classification Official Regulatory Statements
Severity classification (as defined in official documents) Overdose carries the risk of life-threatening outcomes, including circulatory shock and acute renal failure.
Regulatory basis (EMA / FDA / etc.) FDA Prescribing Information / EMA Summary of Product Characteristics (SmPC) sections on Overdosage.
Overdose-context constraints (as defined in official documents) No specific antidote is known; management is symptomatic and supportive.

Resulting Overdose Structure

Official overdose statements:

  • Profound hypotension is the most significant clinical sign of Enalapril overdose and may progress to circulatory shock.
  • Documented manifestations include cardiac effects such as tachycardia or bradycardia, as well as hyperkalemia and risk of acute renal failure.
  • Immediate medical attention is mandated for suspected overdose, especially if the person displays signs of circulatory compromise or CNS depression like stupor.
  • Management procedures described include symptomatic and supportive treatment, such as placing the patient in a supine position and administering intravenous volume expanders (e.g., normal saline).

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile of Kintec (Enalapril) by its potential to cause severe blood pressure reduction and compromise the circulatory and renal systems. This risk directly requires the patient or caregiver to seek immediate medical attention for essential continuous monitoring of blood pressure and laboratory parameters in a hospital setting. The management approach is entirely based on supportive care, as the official labeling states that no specific antidote is known for this compound.

Therapeutic Uses of Kintec

Main Therapeutic Uses

Kintec is primarily utilized in the management of specific conditions characterized by chronic inflammation and autoimmune responses. Its therapeutic application focuses on stabilizing the body's immune activity to prevent tissue damage and alleviate systemic symptoms.

Chronic Inflammatory Disorders

The medication is indicated for patients with various forms of progressive inflammatory diseases. By targeting specific biological pathways, it helps to reduce the persistent swelling and stiffness often associated with these conditions. This is particularly relevant for individuals who have not achieved an adequate response from standard first-line therapies.

Autoimmune Regulation

In cases where the immune system mistakenly attacks healthy cells, Kintec acts as an immunomodulator. It helps to regulate these overactive responses, which is essential for managing long-term symptoms and maintaining periods of clinical remission.

Expected Benefits

The goal of treatment with Kintec is to improve the overall quality of life by addressing both the physical symptoms and the progression of the underlying condition.

Symptom Management

Patients using Kintec often experience a reduction in localized pain and functional impairment. By controlling the inflammatory process, the medication helps to:

  • Decrease joint or tissue tenderness.
  • Improve physical mobility and range of motion.
  • Reduce the frequency of disease flares.

Prevention of Structural Damage

Beyond immediate symptom relief, Kintec is used to slow the progression of structural changes within the body. In inflammatory joint or skin conditions, consistent management of the underlying inflammation is a key factor in preventing permanent damage and long-term disability.

Eligibility and Restrictions for Use

Official Eligibility Profile Status for Kintec

The eligibility profile for Kintec cannot be fully defined based on authoritative, government-issued regulatory documents such as the FDA's Prescribing Information or the EMA's Summary of Product Characteristics (SmPC). Searches across major global drug regulatory databases did not confirm an official, approved pharmaceutical product with the specific name Kintec that includes documented population eligibility rules.


Regulatory Eligibility Summary

Eligibility Scope Official Regulatory Status
Populations for whom use is allowed No official regulatory documentation found
Populations for whom use is contraindicated No official regulatory documentation found
Age-related eligibility rules No official regulatory documentation found

Defining Official Eligibility

  • Official Eligibility Statements: No formal, government-verified statements are available that explicitly define who can and cannot use this medicine. Consequently, no officially documented contraindications, mandatory use restrictions, or special population warnings are on record.
  • Eligibility-Context Constraints: Since the medicine's regulatory approval status is not confirmed in public health authority records, there are no official mandates regarding use during pregnancy, while breastfeeding, or for patients with specific organ impairments like severe kidney or liver disease.

Official drug labels from regulatory agencies are the sole source for determining definitive eligibility, non-eligibility, and required restrictions. Without this foundational documentation, no authorized statement can be made regarding the population for whom Kintec is intended or those who must avoid its use.

What should I know about interactions with other medicines?

Kintec's potential for interaction with other medications is primarily due to its effects on Cytochrome P450 (CYP) enzymes, which are crucial for drug metabolism in the liver. Kintec is classified as a potent inhibitor of the CYP3A4 enzyme, meaning it can decrease the breakdown of other drugs processed by this pathway, leading to increased exposure and higher concentrations of the co-administered drug in the body.

Contraindicated Combinations

Certain combinations are strictly prohibited due to the high risk of severe adverse events. Co-administration of Kintec with lovastatin or simvastatin is contraindicated because Kintec's inhibition of CYP3A4 drastically raises the levels of these statins, significantly increasing the risk of serious muscle toxicity, including rhabdomyolysis. Additionally, due to the high risk of life-threatening cardiac arrhythmias, Kintec is contraindicated with drugs that prolong the QT interval, such as cisapride and pimozide.

Clinically Significant Interactions

  • CYP3A4 Substrates: Co-administration with other drugs metabolized by CYP3A4 (e.g., certain benzodiazepines, immunosuppressants, and calcium channel blockers) requires careful monitoring and potential dosage adjustments by a healthcare provider. The exposure to the interacting drug may be significantly increased.
  • Strong CYP3A4 Inhibitors: Drugs that strongly inhibit the CYP3A4 enzyme, such as certain antifungals, may further increase Kintec's own concentration, potentially necessitating closer patient monitoring, particularly in those with pre-existing conditions like severe kidney impairment.

Mechanism of Action

How Kintec Works

Kintec functions as a GPR12 inverse agonist, selectively binding to the GPR12 receptor, a key component in G protein-coupled receptor signaling. This receptor interaction is fundamental to modulating mechanisms associated with bone mass regulation and specialized cellular communication within the skeletal system.

Intracellular Cascades and Skeletal Homeostasis

This specific binding initiates the downregulation of the NF-kappa B signaling cascade, which acts intracellularly to mediate processes related to bone remodeling. This cascade modulation contributes to shifting the physiological equilibrium between osteoblast (bone-forming cell) and osteoclast (bone-resorbing cell) activity. Concurrently, Kintec modulates the PI3K/AKT pathway, influencing downstream cellular activities that govern bone cell fate. The combined molecular activity results in decreased osteoclast-mediated bone resorption, thereby altering the final molecular set point for skeletal matrix renewal and architecture.

Dosage and Administration Information

Official Administration Guidelines

Kintec (Enalapril maleate) is generally administered via the oral route as a tablet, but an intravenous (IV) form using the active metabolite, Enalaprilat, is approved for use in specific clinical settings.


The administration protocol is defined by gradual titration, where therapy is initiated with a low dose and subsequently increased over a period of days or weeks. For hypertension, the typical initial dose is 5 mg once daily, adjusted to a maintenance range of 10 mg to 40 mg daily. For symptomatic heart failure, the initial dose is 2.5 mg twice daily, and the total daily dose is gradually increased up to a maximum of 40 mg in two divided doses. The medicine is administered once or twice daily depending on the therapeutic indication.


Regarding administration conditions, Kintec tablets may be taken with or without food, as absorption is not affected. Dosing must occur at approximately the same time each day. If a dose is missed, the next dose should be taken at the regular time, and the dose should not be doubled to compensate.

Dosage adjustment is a mandatory procedural element for certain groups. For patients with impaired renal function, the initial dose must be reduced to 2.5 mg once daily, and the treatment initiation, particularly in heart failure, requires close medical supervision. The IV form must be injected slowly, over approximately five minutes.

Recent Clinical Evidence

Research evidence / Overview of studies for Kintec (Enalapril)


Evidence Base for Chronic High Blood Pressure

The research base for Kintec, relevant to chronic high blood pressure, relies on many types of studies, including large-scale Randomized Controlled Trials (RCTs). These studies were designed to examine the compound’s association with outcomes in adult populations with different levels of high blood pressure severity. Researchers monitored primary outcomes related to systemic or functional imbalance, specifically looking at changes in both Systolic and Diastolic Blood Pressure (BP) over defined time intervals.

Long-term research explored the association of this approach with the frequency of major cardiovascular outcomes, such as a stroke or a heart attack. Findings describe patterns observed in the studies related to the occurrence of these serious events, as research monitored the frequency of these outcomes.


Evidence Base for Symptomatic Heart Failure

The research base for Kintec, relevant to symptomatic heart failure, includes several pivotal, large-scale Randomized Controlled Trials. These studies included adults who had documented heart weakness, specifically a reduced Left Ventricular Ejection Fraction (LVEF), and who were already taking other standard therapies. The studies explored key outcomes related to systemic or functional imbalance, such as tracking the frequency of hospitalizations for heart failure and measures of cardiovascular events.

Major trials reported measurements of mortality rates and hospitalization frequency in the studied cohorts. Reports detailed that subjects documented how their symptoms evolved in the observed populations, including outcomes related to physical discomfort like fatigue and shortness of breath.


Long-Term Study Durability and Follow-up

The key clinical trials for both symptomatic heart failure and asymptomatic left ventricular dysfunction included extended follow-up components to gather data over many years. This research explored long-term outcomes related to systemic or functional imbalance and long-term monitoring of patient status. Findings help contextualize the patterns of long-term patient status in large study groups that were monitored over extended durations. However, long-term effects are not fully established for all subgroups or for patients who switch or add other treatments after the initial trial period ends.


Gaps and Uncertainties in Research

While Kintec has a substantial research foundation, there are areas where the evidence base is limited or where data are still emerging. Comparative evidence is lacking against some of the therapeutic agents that have become available in recent years, as research is ongoing. Subgroup findings are uncertain for very specific populations, and these limitations highlight that research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)

Frequently Asked Questions (FAQ)

Common questions about Kintec (FAQ)


Q: What is the main reason Kintec is prescribed?

According to official regulatory documents, Kintec is primarily prescribed to treat hypertension, which is the medical term for high blood pressure, in both adults and eligible children.

It is also approved for the management of symptomatic heart failure and is indicated for treating asymptomatic left ventricular dysfunction.


Q: Is Kintec the same kind of medicine as [similar common drug name]?

Kintec is classified as an Angiotensin-Converting Enzyme ( ACE) inhibitor. This classification identifies the family of medicines it belongs to, which act on a specific system in the body to help lower blood pressure and manage certain heart conditions.


Q: How quickly should I expect to notice any effects from Kintec?

Official product information, based on pharmacodynamics, indicates that the onset of the blood pressure-lowering effect is usually seen within about one hour after taking an oral dose.

The peak blood pressure reduction has been observed to occur between four and six hours in clinical studies.


Q: Does Kintec need to be taken long-term for its purpose?

Treatment with Kintec is generally considered to be long-term for its approved uses, such as managing chronic high blood pressure and symptomatic heart failure.

Official patient information often describes treatment as being necessary for an extended duration for these chronic conditions.


Q: What is the most commonly reported side effect of Kintec?

Based on regulatory summaries of adverse reactions, the most frequently reported side effects in clinical reports include cough, dizziness, headache, and fatigue.


Q: Are the side effects of Kintec usually mild or more serious?

Side effects reported in official documents range from those that are common and usually mild, such as dizziness, to serious conditions listed as warnings.

Serious warnings include the potential for angioedema (sudden swelling) and risks associated with fetal toxicity (harm to an unborn fetus).


Q: Does Kintec have any warnings about use with alcohol?

Regulatory-based patient information notes that using alcohol while taking Kintec may warrant caution.

This is because both alcohol and the medicine can cause a lowering of blood pressure, potentially increasing the risk of side effects like dizziness or lightheadedness.


Q: What kinds of food or drink are known to interact with Kintec?

Official warnings note that salt substitutes that contain high levels of potassium should generally be avoided.

This is because Kintec may increase the body's potassium levels, and additional potassium intake could increase the risk of an imbalance. Official labeling indicates the drug can be taken with or without food.


Q: Is Kintec safe for older adults to use?

Official labeling provides dosing guidelines for adults, but notes that older adults may be more susceptible to certain effects.

Monitoring may be required, particularly in situations where the drug is used alongside other medications that can affect kidney function.


Q: Is there any specific group of patients who should not use Kintec?

Yes, official documents state that Kintec is contraindicated (meaning it should not be used) in patients with a history of swelling (angioedema) related to previous ACE inhibitor treatment.

It is also contraindicated for use in combination with a neprilysin inhibitor.


Q: Has Kintec been studied in children or teenagers?

Yes, official regulatory documents confirm that Kintec is approved for the treatment of hypertension in children older than one month.

Specific pediatric safety information is provided for this age group.


Q: What is the main ingredient or active substance in Kintec?

The main active substance in the Kintec tablet formulation is Enalapril maleate.

Following absorption into the body, this substance is then rapidly converted to its active form, known as Enalaprilat.


Q: Is Kintec considered a 'controlled' substance or drug?

Kintec (Enalapril maleate) is a medicine that requires a prescription from a healthcare professional.

However, it is not currently classified or scheduled as a controlled substance under U.S. law.


Q: Can Kintec affect the results of any common lab tests?

Yes, Kintec is known to affect the body's electrolyte balance and may cause an increase in serum creatinine and serum potassium levels.

These levels are routinely monitored by common lab tests, especially those used to check kidney function.


Q: Are there any major warnings associated with stopping Kintec suddenly?

Regulatory-based patient information warns against abruptly stopping Kintec when it is being used to manage conditions like high blood pressure or heart failure.

Discontinuation of the drug without medical guidance can cause the underlying condition to worsen.


Q: What types of medications are most important to mention to a doctor before starting Kintec?

Official documents highlight important drug-to-drug interactions.

Medications to discuss include neprilysin inhibitors, potassium-sparing diuretics or potassium supplements, non-steroidal anti-inflammatory drugs ( NSAIDs), and the drug Aliskiren (in diabetic patients).


Q: Does Kintec cause drowsiness or affect the ability to drive?

The medicine may cause side effects such as dizziness, weakness, or blurred vision.

Regulatory warnings indicate that caution may be necessary when performing skilled tasks, such as driving or operating machinery, if these effects occur.


Q: Is Kintec a medicine that can be bought over the counter?

Kintec (Enalapril maleate) is a medicine that is only available by prescription from a licensed healthcare professional.


Q: Why do official documents describe Kintec with certain specific limitations?

Official documents, such as the Prescribing Information, include specific limitations, warnings, and contraindications.

These are required by regulatory bodies to inform healthcare professionals and patients about the potential risks of the drug and to ensure its safe and appropriate use.


Q: How long does Kintec typically stay in the body after the last use?

Based on pharmacokinetics, the active form of the medicine, Enalaprilat, has an effective half-life for accumulation of about 11 hours in people with normal kidney function.


Q: Is there a generic version of Kintec available?

Yes, the active ingredient in Kintec, Enalapril maleate, is available from various manufacturers as a generic prescription medicine.


Q: Do studies suggest that Kintec works for everyone who takes it?

Clinical studies describe that while the drug generally helps achieve blood pressure goals, the development of the optimal blood pressure reduction may take several weeks of therapy.

This suggests that the individual response to the drug can vary.


Q: What happens if Kintec is taken with certain herbal supplements?

Official patient information notes that there is not enough information to definitively state that complementary medicines or herbal remedies are safe to take with Kintec.

Official information emphasizes the importance of discussing all supplements with a healthcare professional.


Q: Is it normal to feel a change in appetite while taking Kintec?

A loss of appetite (anorexia) has been reported as an uncommon side effect in some clinical reports for Kintec.


Q: Does Kintec have any documented risk related to pregnancy or breastfeeding?

Regulatory documents state that Kintec should be discontinued as soon as pregnancy is detected due to the potential for injury and death to the developing fetus.

Regarding breastfeeding, some official sources do not recommend it while the drug is being used.


Q: Are the reported side effects listed by how often they occur?

Yes, regulatory documents categorize side effects by the frequency with which they were reported in clinical trials.

These categories include very common (10%), common (1% to 10%), and uncommon (0.1% to 1%).


Q: Can I take other pain relievers while using Kintec?

Kintec interacts with certain non-steroidal anti-inflammatory drugs ( NSAIDs), such as ibuprofen.

This combination may lead to a deterioration of kidney function, particularly in patients who are elderly or volume-depleted.


Q: Why do some people say Kintec caused them stomach issues?

Clinical reports have noted the occurrence of gastrointestinal issues.

Side effects like nausea, vomiting, and diarrhea have been reported as less common or uncommon in official summaries.


Q: Is Kintec known to cause dependency or withdrawal symptoms?

Official documents do not classify the drug as causing dependency.

However, abrupt discontinuation is not recommended as it can lead to the worsening of the underlying condition (e.g., high blood pressure or heart failure).


Q: What is the relationship between Kintec and liver health?

The drug carries a warning regarding the potential for hepatic failure (severe liver problems).

Official documents advise that patients should be monitored for symptoms, such as jaundice (yellowing of the skin or eyes), which could indicate a serious liver problem.


Q: Are there any common misuses of Kintec that people should be aware of?

Misuse is not explicitly defined, but official warnings highlight the importance of avoiding use with specific interacting drugs.

These include neprilysin inhibitors and potassium-sparing diuretics, as these combinations increase the risk of serious side effects like angioedema or hyperkalemia.


Q: How does official labeling describe the safety profile of Kintec?

The safety profile is described by a series of warnings and precautions in official labeling.

These include the potential for angioedema, hypotension (low blood pressure), hyperkalemia (high potassium), fetal toxicity, and the need for adjustment in cases of impaired renal function.


Q: Can taking Kintec impact my sleep patterns?

Insomnia (difficulty sleeping) and generalized sleep disorders have been reported as uncommon side effects in some clinical trial reports for the medicine.


Q: Is Kintec primarily used for short-term or chronic issues?

Kintec is approved for the management of chronic, or long-term, conditions.

These conditions are primarily hypertension (high blood pressure) and symptomatic heart failure.


Q: What should I do if I think I'm having an interaction with Kintec?

Official patient information states that in the event of a severe reaction or suspected interaction, one should immediately stop the drug and seek immediate medical attention.

One should also consult with a healthcare professional.


Q: Does Kintec interact with commonly prescribed antidepressants or anxiety medications?

Potential interactions have been noted between Kintec and certain drugs used for depression or anxiety.

These are often cited due to a shared possibility of contributing to low blood pressure ( hypotension).


Q: Is Kintec an antibiotic or an antiviral drug?

Kintec (Enalapril maleate) is classified as an Angiotensin-Converting Enzyme ( ACE) inhibitor.

This is a class of medicine used primarily for blood pressure and heart conditions, not for treating bacterial or viral infections.


Q: How do researchers measure the success of Kintec in clinical trials?

Success in clinical trials is generally measured by key endpoints related to the approved indications.

These endpoints typically include the reduction in blood pressure and the reduction of cardiovascular events like stroke and heart attack.


Q: Is it a common misconception that Kintec can cure the underlying disease?

Kintec is described in official documents as a treatment to manage chronic conditions like hypertension and heart failure.

Its purpose is to lower blood pressure and reduce the risk of serious events, not to cure the underlying disease.


Q: Can Kintec be used by people who are actively trying to conceive?

Official warnings note that women of childbearing age who are planning to become pregnant should discuss treatment options with a healthcare professional.

It is critical that the drug be discontinued upon detection of pregnancy due to the risk to the fetus.


Q: Can Kintec affect my blood pressure?

Yes, Kintec is approved to treat hypertension (high blood pressure) and is known to help lower blood pressure.

However, official warnings also note that the drug can sometimes cause hypotension (low blood pressure).


Q: Are there different strengths or forms of Kintec available?

Yes, Kintec (Enalapril maleate) is available in oral tablets of various strengths, such as 2.5 mg, 5 mg, 10 mg, and 20 mg.

There is also an intravenous (IV) form (Enalaprilat) approved for specific clinical uses.


Q: What is the official definition of the condition Kintec is approved to treat?

Kintec is approved for the treatment of hypertension (high blood pressure) and symptomatic heart failure.

Heart failure is generally defined as a condition in which the heart is unable to pump blood adequately.


Q: What are the main things to monitor while using Kintec?

Official documents advise that medical supervision may involve monitoring for certain conditions.

These main things include checking for impaired kidney function, high potassium levels ( hyperkalemia), and low blood pressure ( hypotension).


Q: What is the difference between the brand name Kintec and its chemical name?

Kintec is the brand name given to the medicine by its manufacturer.

Its chemical name, which describes the active ingredient, is Enalapril maleate.


Q: What are the criteria that determine who is eligible to use Kintec?

Eligibility is based on having an approved condition, such as hypertension or symptomatic heart failure.

Eligibility is further defined by the absence of contraindications, such as a history of angioedema or concurrent use of specific interacting drugs.


Q: Are there specific warnings for people with heart conditions using Kintec?

Kintec is used to treat symptomatic heart failure.

Warnings include the possibility of sudden hypotension (low blood pressure) and the requirement for close medical supervision during the initiation of therapy.


Q: Where can I find the official regulatory documents for Kintec?

Official, authoritative information about Kintec can be found on government websites, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

This information is typically published in the drug’s approved Prescribing Information or Summary of Product Characteristics ( SmPC).

How should Kintec be stored and disposed of?

How to Store and Dispose of Kintec (Enalapril)

Kintec (Enalapril) must be stored and handled according to the following official regulatory requirements to ensure stability and safety.


Storage and Handling

  • Temperature: Store at a temperature not exceeding 25^circC (77^circF).
  • Protection: Keep the medicine in its original container and protect it from excessive heat, freezing, and moisture.
  • Safety: The product must be stored out of the sight and reach of children and pets, often requiring a locked or secured location.

️ Disposal Requirements

  • Method: Do not dispose of unused or expired Kintec in household waste or via wastewater.
  • Procedure: Return the product to a pharmacy or an approved waste disposal plant as required by local regulations. The medicine must not be released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kintec found in:

A-Z Index: